Immuno‐Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega‐3 Fatty Acids in Metabolic Syndrome
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Omega‐3 fatty acid consumption has been suggested to be beneficial for the prevention of type 2 diabetes mellitus (T2DM). Its effects have been attributed to anti‐inflammatory activity, with the inhibition of arachidonic acid metabolism playing a central role. However, a more recent view is that omega‐3 fatty acids play an active role as the precursors of potent, specialized pro‐resolving mediators (SPMs), such as resolvins, protectins, and maresins. Docosahexaenoic acid (DHA)‐ and eicosapentaenoic‐acid‐derived SPMs are identified in the adipose tissue but the levels of certain SPMs (e.g., protectin D1) are markedly reduced with obesity, suggesting adipose SPM deficiency, potentially resulting in unresolved inflammation. Supplementation of the biosynthetic intermediates of SPM (e.g., 17‐hydroxy‐DHA) or omega‐3 fatty acids increases the level of adipose SPMs, reduces adipose inflammation (decrease in macrophage accumulation and change to less inflammatory macrophages), and enhances insulin sensitivity. The findings from studies using rodent obesity models must be translated to humans. It will be important to further elucidate the underlying mechanisms by which obesity reduces the levels of and the sensitivity to SPM in adipose tissues. This will enable the development of nutrition therapy to enhance the effects of omega‐3 fatty acids in the prevention and/or treatment of T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
TLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Inflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319
Inflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212
Nathan, C., & Ding, A. (2010) · Cell · doi:10.1016/j.cell.2010.02.029 · Cited by 2,183
Cited by
Ferreira, I., Falcato, F., Bandarra, N., & Rauter, A. P. (2022) · Molecules · doi:10.3390/molecules27051677 · Cited by 120
“HDHAs include the specialized pro-resolving mediators (SPMs) or docosanoids, comprising D-series resolvins (RvD), protectins (PD), and maresins (MaRs) (Figure 2), which are available at sites of acute inflammation, acting in a specific tissue [23], and potent lipid mediators, with benefits of the prevention and treatm…”
BackgroundBetter prepare for the next one. Lifestyle lessons from the COVID-19 pandemic
Galli, F., Reglero, G., Bartolini, D., & Visioli, F. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100193 · Cited by 47
“3. Sedentary lifestyle, overweight/obesity, and metabolic diseases.”
Suzumura, A., Terao, R., & Kaneko, H. (2020) · Antioxidants · doi:10.3390/antiox9100920 · Cited by 44
“Resolvins are produced from DHA and EPA and are denoted as the D-series (RvD1–RvD6) and E-series (RvE1–RvE3), respectively, while certain isomers of RvDs termed aspirintriggered resolvin Ds (AT-RvDs) require acetylated COX-2 in the presence of aspirin or other nonsteroid anti-inflammatory drugs for their synthesis [62…”
Background
Metadata
- Authors
- Kwon, Y.
- Venue
- Molecular Nutrition & Food Research
- Publisher
- Wiley
- Published
- 2019-12-15
- Volume
- 64
- Issue
- 4
- Pages
- e1900824-e1900824
- ISSN
- 1613-4125 (ISSN-L)
- 1613-4133
- OpenAlex
- W2993296725
- Cited by
- 84
- References
- 35
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.